Abstract
Hemophilus influenzae type b polysaccharide-Afeisseria meningitidis group B outer membrane protein complex vaccine was administered in a single dose to 38 children ages 24-53 mo (group 1) and to 78 children ages 12-23 mo (group 2) and in two doses to 84 children ages 2-11 mo (group 3). The geometric mean concentration of the capsular antibody before and after the vaccine regimen, respectively, were 0.35 ng/ml and 12.59 (ig/ml in group 0.18 ng/ml and 4.79 ng/ml in group 2, and 0.15 ng/ml and 3.80 ig/ml in group 3. After completing the vaccine regimen, concentrations of capsular antibody were >0.15 Hg/ml in 199 (99.5%) of the 200 children and >1.0 ng/ml in 168 (84%) of the children. There were no serious and few minor adverse reactions to the vaccine. This vaccine is immunogenic in infants and young children.
Original language | English (US) |
---|---|
Pages (from-to) | 1064-1067 |
Number of pages | 4 |
Journal | Journal of Infectious Diseases |
Volume | 160 |
Issue number | 6 |
DOIs | |
State | Published - Dec 1989 |
Funding
Receivedfor publication 17February 1989and in revisedform 5 July 1989. Written informed consent was obtained from the parents of subjects in this study. This work was supported in part by grants from Merck Sharp and Dohme, West Point, Pennsylvania, and the Children's Clinical Research Centers (RR-OOI25), General Clinical Research Centers Program, National Institutes of Health. Please address requests for reprints or for a detailed description of the biochemical composition of the vaccine to Dr. Eugene D.Shapiro, Department of Pediatrics, YaleUniversitySchool of Medicine, P.O. Box 3333, New Haven, CT 06510-8064.
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy